Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 5, 2024

Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

Author(s)Ryan Haumschild, PharmD, MS, MBA, Roy Beveridge, MD, Brian T. Hill, MD, PhD

A panel of experts discuss combination regimens with BTK inhibitors.

Episodes in this series

A panel of 4 experts on CLL

EP. 1 Recent Trends and Innovations in the Management of CLL

A panel of 4 experts on CLL

EP. 2 CLL Treatment Landscape: Overview of BTK Inhibitors

A panel of 4 experts on CLL

EP. 3 Evaluating Value of BTK Inhibitors in CLL Treatment

A panel of 4 experts on CLL

EP. 4 Factors Influencing Choice of Second-Generation BTKi Monotherapy

A panel of 4 experts on CLL

EP. 5 Empowering Patients: Key Considerations for BTK Inhibitor Adherence

A panel of 4 experts on CLL

EP. 6 Optimizing Therapy Sequencing in CLL

A panel of 4 experts on CLL

EP. 7 Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

A panel of 4 experts on CLL

EP. 8 Decision-Making in CLL: The Role of Real-World Evidence

A panel of 4 experts on CLL

EP. 9 Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

A panel of 4 experts on CLL

EP. 10 Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

A panel of 4 experts on CLL

EP. 11 Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

A panel of 4 experts on CLL

EP. 12 The Inflation Reduction Act: Implications for Patient Access in CL

A panel of 4 experts on CLL

EP. 13 Patient Access Advocacy for BTK Inhibitors

A panel of 4 experts on CLL

EP. 14 Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Video content above is prompted by the following question(s):

What emerging evidence is there for combination therapies of BTK inhibitors with new and existing therapies to enhance treatment efficacy in CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Kerry Rogers, MD

Managing Toxicity, Sequencing for Long-Term BTKIs: Kerry Rogers, MD

ByMaggie L. Shaw,Kerry Rogers, MD

June 25th 2026

Zanubrutinib | Image Credit: © luchschenF-stock.adobe.com

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

ByMaggie L. Shaw

June 24th 2026

Adam Kittai, MD

Balancing Cost, Utilization, and Risk in CLL Treatment: Adam Kittai, MD

ByMaggie L. Shaw,Adam S. Kittai, MD

June 23rd 2026

ChronicLL | Image Credit: © Saiful52-stock.adobe.com

Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL

ByMaggie L. Shaw

June 16th 2026

The Daily Burden of BTK Inhibitor Therapy: Kerry Rogers, MD

ByMaggie L. Shaw,Kerry Rogers, MD

June 8th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

Health Equity & Access Weekly Roundup: June 26, 2026

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD